Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says

MT Newswires Live07-03

Exelixis (EXEL) offers balanced risk-reward ahead of several key catalysts, with its Zanzalintinib therapy well positioned for success in a non-clear cell renal cell carcinoma, or nccRCC, trial readout in the second half of 2026 that could lift the stock, UBS Securities said.

The brokerage said Zanzalintinib's expansion into additional indications will be critical to maintaining Exelixis' value after Cabometyx loses exclusivity. Even if the nccRCC readout is positive, UBS said there remains debate over whether Zanzalintinib can outperform Cabometyx in renal cell carcinoma.

The firm also said the therapy's potential launch in metastatic colorectal cancer remains another important catalyst, with the US Food and Drug Administration's target action date for the company's new drug application set for Dec. 3.

UBS models Q2 product revenue of $569 million, below the Visible Alpha consensus estimate of $584 million. The brokerage maintained its 2026 product revenue estimate of $2.3 billion, compared with the Visible Alpha consensus of $2.4 billion.

The firm raised its price target on Exelixis to $52 from $43 and reiterated its neutral rating.

Shares of Exelixis were up 3% in Thursday trading.

Price: 55.59, Change: +1.63, Percent Change: +3.02

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2648681630?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-03 00:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648681630","market":"us","top_or_hot":-1,"title":"Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says","media":"MT Newswires Live","content":"<html><body><p> Exelixis (EXEL) offers balanced risk-reward ahead of several key catalysts, with its Zanzalintinib therapy well positioned for success in a non-clear cell renal cell carcinoma, or nccRCC, trial readout in the second half of 2026 that could lift the stock, UBS Securities said.</p><p>The brokerage said Zanzalintinib's expansion into additional indications will be critical to maintaining Exelixis' value after Cabometyx loses exclusivity. Even if the nccRCC readout is positive, UBS said there remains debate over whether Zanzalintinib can outperform Cabometyx in renal cell carcinoma.</p><p>The firm also said the therapy's potential launch in metastatic colorectal cancer remains another important catalyst, with the US Food and Drug Administration's target action date for the company's new drug application set for Dec. 3.</p><p>UBS models Q2 product revenue of $569 million, below the Visible Alpha consensus estimate of $584 million. The brokerage maintained its 2026 product revenue estimate of $2.3 billion, compared with the Visible Alpha consensus of $2.4 billion.</p><p>The firm raised its price target on Exelixis to $52 from $43 and reiterated its neutral rating.</p><p>Shares of Exelixis were up 3% in Thursday trading.</p><p>Price: 55.59, Change: +1.63, Percent Change: +3.02</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-03 00:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Exelixis (EXEL) offers balanced risk-reward ahead of several key catalysts, with its Zanzalintinib therapy well positioned for success in a non-clear cell renal cell carcinoma, or nccRCC, trial readout in the second half of 2026 that could lift the stock, UBS Securities said.</p><p>The brokerage said Zanzalintinib's expansion into additional indications will be critical to maintaining Exelixis' value after Cabometyx loses exclusivity. Even if the nccRCC readout is positive, UBS said there remains debate over whether Zanzalintinib can outperform Cabometyx in renal cell carcinoma.</p><p>The firm also said the therapy's potential launch in metastatic colorectal cancer remains another important catalyst, with the US Food and Drug Administration's target action date for the company's new drug application set for Dec. 3.</p><p>UBS models Q2 product revenue of $569 million, below the Visible Alpha consensus estimate of $584 million. The brokerage maintained its 2026 product revenue estimate of $2.3 billion, compared with the Visible Alpha consensus of $2.4 billion.</p><p>The firm raised its price target on Exelixis to $52 from $43 and reiterated its neutral rating.</p><p>Shares of Exelixis were up 3% in Thursday trading.</p><p>Price: 55.59, Change: +1.63, Percent Change: +3.02</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EXEL","symbol_name":"伊克力西斯","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2648681630","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2648681630","pubTimestamp":1783008131,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Exelixis  offers balanced risk-reward ahead of several key catalysts, with its Zanzalintinib therapy well positioned for success in a non-clear cell renal cell carcinoma, or nccRCC, trial readout in the second half of 2026 that could lift the stock, UBS Securities said.The brokerage said Zanzalintinib's expansion into additional indications will be critical to maintaining Exelixis' value after Cabometyx loses exclusivity. Even if the nccRCC readout is positive, UBS said there remains debate over whether Zanzalintinib can outperform Cabometyx in renal cell carcinoma.The firm also said the therapy's potential launch in metastatic colorectal cancer remains another important catalyst, with the US Food and Drug Administration's target action date for the company's new drug application set for Dec. 3.UBS models Q2 product revenue of $569 million, below the Visible Alpha consensus estimate of $584 million. The brokerage maintained its 2026 product revenue estimate of $2.3 billion, compared wi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EXEL":"伊克力西斯","BK4532":"文艺复兴科技持仓","BK4139":"生物科技"},"translate_title":"瑞银表示，Exelixis在关键催化剂出现之前面临平衡的风险回报","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EXEL":1.5},"content_text":"Exelixis (EXEL) offers balanced risk-reward ahead of several key catalysts, with its Zanzalintinib therapy well positioned for success in a non-clear cell renal cell carcinoma, or nccRCC, trial readout in the second half of 2026 that could lift the stock, UBS Securities said.The brokerage said Zanzalintinib's expansion into additional indications will be critical to maintaining Exelixis' value after Cabometyx loses exclusivity. Even if the nccRCC readout is positive, UBS said there remains debate over whether Zanzalintinib can outperform Cabometyx in renal cell carcinoma.The firm also said the therapy's potential launch in metastatic colorectal cancer remains another important catalyst, with the US Food and Drug Administration's target action date for the company's new drug application set for Dec. 3.UBS models Q2 product revenue of $569 million, below the Visible Alpha consensus estimate of $584 million. The brokerage maintained its 2026 product revenue estimate of $2.3 billion, compared with the Visible Alpha consensus of $2.4 billion.The firm raised its price target on Exelixis to $52 from $43 and reiterated its neutral rating.Shares of Exelixis were up 3% in Thursday trading.Price: 55.59, Change: +1.63, Percent Change: +3.02","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2648681630","isCrawlerRequest":true}